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Abstract
Gallbladder cancer (GBC) is a multifactorial disease with complex interplay between multiple genetic variants. We performed
Classification and Regression Tree Analysis (CART) and Grade of Membership (GoM) analysis to identify combinations of
alleles among the DNA repair, inflammatory and apoptotic pathway genetic variants in modifying the risk for GBC. We
analyzed 16 polymorphisms in 8 genes involved in DNA repair, apoptotic and inflammatory pathways to find out
combinations of genetic variants contributing to GBC risk. The genes included in the study were XRCC1, OGG1, ERCC2, MSH2,
CASP8, TLR2, TLR4 and PTGS2. Single locus analysis by logistic regression showed association of MSH2 IVS1+9G.C
(rs2303426), ERCC2 Asp312Asn (rs1799793), OGG1 Ser326Cys (rs1052133), OGG1 IVS4-15C.G (rs2072668), CASP8 -652 6N
ins/del (rs3834129), PTGS2 -1195G.A (rs689466), PTGS2 -765G.C (rs20417), TLR4 Ex4+936C.T (rs4986791) and TLR2 –196
to –174del polymorphisms with GBC risk. The CART analysis revealed OGG1 Ser326Cys, and OGG1 IVS4-15C.G
polymorphisms as the best polymorphic signature for discriminating between cases and controls. In the GoM analysis, the
data was categorized into six sets representing risk for GBC with respect to the investigated polymorphisms. Sets I, II and III
described low intrinsic risk (controls) characterized by multiple protective alleles while sets IV, V and VI represented high
intrinsic risk groups (GBC cases) characterized by the presence of multiple risk alleles. The CART and GoM analyses also
showed the importance of PTGS2 -1195G.A polymorphism in susceptibility to GBC risk. In conclusion, the present
multigenic approach can be used to define individual risk profiles for gallbladder cancer in North Indian population.
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Introduction
Carcinoma of the gallbladder (GBC) is an aggressive malignancy
and the most common biliary tract tumor in the world with highest
incidence and mortality rates in Northern India (21.5/100,000) [1,2].
Apart from gallstones being the major risk factor, the exact etiology of
GBC is poorly understood [3]. Cancer being a multifactorial disease,
multiple genetic variants along with the environmental and dietary
factors may interact to cause the disease or act as risk modifiers.
Identification of these risk sets of genetic variants causative to the
disease will facilitate in determining individuals at risk for GBC.
Previously, we have studied the role of individual genetic variants
with GBC susceptibility in North Indian population [4,5,6]. Due to
conflicting results obtained in case-control association studies of
complex diseases such as cancer, the current focus is aimed on
searching for gene-gene interactions as a key contributory factor in the
disease outcome. But the analysis of such interactions in case-control
studies is weighed down by one of the major problems, namely, the
curse of dimensionality. Recently, Multifactor-Dimensionality Reduc-
tion (MDR) approach [7] and tree-based techniques, classification and
regression trees (CART) and random forest (RF), have been used to
detect interactions in large-scale association studies [8]. The strength of
these methodologies is their ability to identify association in cases of
small sample sizes and low penetrance of candidate single nucleotide
polymorphisms (SNPs). Therefore, we have extended our previous
work by jointly investigating 16 SNP genotypes in 8 genes belonging to
DNA repair pathway [ERCC2 Asp312Asn (Ex10-16G.A; rs1799793)
and Lys751Gln (Ex23+61A.C; rs13181); MSH2 (IVS1+9G.C;
rs2303426) and (-118T.C; rs2303425); OGG1 Ser326Cys (Ex6-
315C.G; rs1052133) and (IVS4-15C.G; rs2072668); XRCC1
Arg194Trp (Ex6-22C.T; rs1799782) and Arg399Gln (Ex10-4A.G;
rs25487)], apoptotic pathway [CASP8 -652 6N ins/del (rs3834129),
Asp302His (Ex13+51G.C; rs1045485) and (IVS12-19G.A;
rs3769818)] and inflammatory pathway [PTGS2 (-1195G.A;
rs689466), (-765G.C; rs20417) and (Ex10+837T.Co r+8473;
rs5275); TLR2 –196 to –174del (TLR2 D22); and TLR4 Thr399Ile
(Ex4+936C.T; rs4986791)], avoiding the problem of dimensionality
and multiple comparisons. These polymorphisms have been reported
to alter the risk for developing various malignancies [9,10,11,12,13,14].
Materials and Methods
Ethics Statement
The institutional ethical committee of Sanjay Gandhi Post Graduate
Institute of Medical Sciences (SGPGIMS) approved the study protocol,
and all participants provided written informed consent for the study.
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A total of 460 subjects, including 230 GBC patients and 230
control subjects were enrolled in this study. The GBC patients were
consecutively diagnosed between June 2005 and September 2009.
Gallbladder cancer diagnosis was confirmed for all cases by fine
needle aspirated cell cytology (FNAC) and histopathology. Staging of
cancer was documented according to the AJCC/UICC staging [15].
The inclusion criteria for controls were absence of prior history of
cancer, precancerous lesions and gallstones proven by ultrasonogra-
phy and were frequency-matched to cancer cases on age, gender and
ethnicity. To test the possibility for population stratification, genomic
control method was used as described by Devlin et al [16]. Majority
ofthe femalepatients were housewives and the malepatientswerenot
engaged in any hazardous occupations.
Genotyping
Genomic DNA was isolated from peripheral blood leukocytes.
The polymorphisms were genotyped using the PCR or PCR-
restriction fragment length polymorphism method. The details of
genotyping for studied polymorphisms are shown in Table S1. As
a negative control, PCR mix without DNA sample was used to
ensure contamination free PCR product. Samples that failed to
genotype were scored as missing. Genotyping was performed
without knowledge of the case or control status.
Statistical Analysis
Single Locus Analysis. The sample size was calculated
considering the minor allele frequency (MAF) of the studied
polymorphisms in Caucasian population. The sample size of 230
cases and 230 controls was adequate to give us a power of 80%
(Inheritance mode= log-additive, Genetic effect=2, Type-I error
rate=0.05). Chi-square analysis or two-sided Fisher’s exact test was
used to compare the differences in demographic variables and
genotype distributions of the polymorphisms between cases and
controls. Observed genotype frequencies for all the polymorphisms
in controls were examined for deviation from Hardy–Weinberg
equilibrium (HWE) using a goodness-of-fit x
2-test with one degree
of freedom. Unconditional univariate and multivariate logistic
regression analysis was used to estimate odds ratio (OR) and 95%
confidence interval (CI) adjusted for age and gender to estimate the
risk of gallbladder cancer with the polymorphisms. Risk estimates
were also calculated for a codominant genetic model using the most
common homozygous genotype as reference. Tests of linear trend
using an ordinal variable for the number of copies of the variant
allele (0, 1 or 2) were conducted to assess potential dose–response
effects of genetic variants on gallbladder cancer risk [17]. Standard
adjustments for multiple testing, such as Bonferroni correction, are
too conservative as they assume that tests are independent, which is
usuallynot the casewhen multipletestsareappliedonthe same data
set. We, therefore applied the false-positive report probability
(FPRP) statistical tool to evaluate noteworthiness of the associations
by using the method as described by Wacholder et al [18].
To further support the results of logistic regression, we used
genomic control method by Devlin et al [16]. The software uses a
Bayesian outlier test to determine which markers exhibit
significant linkage disequilibrium with the disorder minimizing
the false positive associations. Also it allows for violations in the
usual model assumption i.e. independence of observations because
in case-control studies affected individuals are more likely to be
related than are controls because they share a genetic disorder and
ideally a common genetic basis for the disorder. This is known as
‘‘cryptic relatedness’’ which almost always produces false positives
even after Bonferroni correction. The software performs these
analyses using Markov chain Monte Carlo (MCMC) algorithms.
Classification and Regression Tree Analysis
(CART). The non-parametric classification and regression tree
analysis was used along with the logistic regression for higher-
order gene-gene interactions using the CART Software (version
6.0, Salford Systems) [19,20]. CART is a binary recursive-
partitioning method that produces a decision tree to identify
subgroups of subjects at higher risk. Specifically, the recursive-
partitioning algorithm in CART software starts at the first node
(with the entire data set) and uses a statistical hypothesis-testing
method—formal inference based recursive modelling—to
determine the first locally optimal split and each subsequent split
of the data set, with multiplicity-adjusted P-values to control tree
growth. This process continues until the terminal nodes have no
subsequent statistically significant splits or the terminal nodes
reach a pre-specified minimum size. The data were divided
randomly into a learning set (90% of the data) and a testing set
(10% of the data). The learning set was used to construct the tree
model, and the testing set was used to internally validate the
resulting tree model. Subgroups of individuals with differential risk
patterns were then identified in the different order of nodes of the
tree structure, indicating the presence of gene–gene and gene–
environment interactions. Logistic regression was used to calculate
the OR and 95% CI in each terminal node of the tree, adjusting
for age and gender. P,0.05 was considered as the threshold of
significance in this study. All statistical analyses were two-sided.
Grade of Membership Analysis (GoM). To investigate all
the genetic factors simultaneously without multiple comparisons,
the Grade of Membership (GoM) analysis was used [21,22].
Information on disease status and genetic variants were used as
internal variables to define the pure types while sex and age were
external variables. The approach taken is termed as latent
classification method that is considered to be ‘fuzzy’ in that each
individual can partially belong to more than one group, here,
genetic risk sets. The GoM analysis framework thus makes very
few distributional assumptions. The GoM models were construc-
ted as described previously [23].
Results
Population characteristics
Baselinecharacteristics of GBCpatients and their age and gender
matched controls are presented in Table 1. Of the 230 GBC cases
and controls, the mean age was 53.0566.40 years (range, 37–72
years) and 54.1268.81 (range, 35–79 years), respectively. The mean
age and gender distributions were not significantly different among
cases and controls, suggesting that the frequency matching was
adequate. Genomic control method ruled out the possibility of
population stratification in our study. Most of the GBC patients
were in advanced stages of cancer (stage III and stage IV). Of the
230 GBC cases, 12 (5.3%) had stage II adenocarcinoma, 76 (33.0%)
stage IIIand 142 (61.7%) stage IV. Allcancer patients wereincident
cases and none of the controls had family history of cancer.
Single Locus Analysis
Table 2 shows the GBC risk related to the studied polymor-
phisms.
Association of ERCC2, MSH2, XRCC1 and OGG1
polymorphisms with GBC. On comparing the genotype
frequency distribution in GBC patients with that of controls, the
homozygous variant genotypes of MSH2 IVS1+9G.C, ERCC2
Asp312Asn and OGG1 Ser326Cys polymorphisms showed statis-
tically significant increased risk for developing GBC (OR=1.83;
OR=2.12; OR=2.48, respectively). The risk due to variant-
containing genotypes (CG+GG) of OGG1 Ser326Cys was also
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CC genotype. The OGG1 IVS4-15C.Gi n t r o n i cp o l y m o r p h i s mw a s
also significantly associated with the risk for GBC following a
dominant mode of inheritance (OR=1.63) (Table 2).
In case of XRCC1 Arg399Gln polymorphism, frequencies of
heterozygote and variant homozygote were significantly different
among in controls as compared to GBC patients (x
2=13.84;
P=0.001; df, 2). These frequency differences were statistically
significant (P=0.039; P=0.003 respectively) and conferred low
risk for GBC (OR=0.57; OR=0.44 respectively) (Table 2). The
protective effect was also significant when variant containing
genotypes (GA+AA) were compared with homozygous wild-type
genotype (P=0.006; OR=0.55) (Table 2).
For the other SNPs in DNA repair genes (ERCC2 Lys751Gln,
MSH2 -118T.Ca n dXRCC1 Arg194Trp), no statistically signifi-
cant associations were observed in the present study (Table 2).
Association of CASP8 polymorphisms with GBC. Fre-
quencies of the CASP8 -652 6N common homozygote, heterozygote
and variant homozygote genotypes were significantly different among
GBC patients and controls (x
2=7.79;P=0.020; df, 2). In the present
study, we found that both heterozygote and variant homozygote
Table 1. Characteristic profile of controls and GBC patients.
Characteristic
Healthy controls
(N=230)
GBC case patients
(N=230)
Gender, n (%)
Male 78(33.9) 79(34.3)
Female 152(66.1) 151(65.7)
Age, mean (SD*) 54.1268.81 53.0566.40
Stages, n (%)
0, I None
II 12(5.3)
III 76(33.0)
IV 142(61.7)
Gallstone present,
n( % )
None 117(51.0)
*SD, standard deviation.
doi:10.1371/journal.pone.0016449.t001
Table 2. Single locus analysis of SNPs investigated.
Gene Polymorphism MAFcontrols MAFcases Ptrend FPRP ORhet
a ORhom
a ORdom
a Prob
b
ERCC2 Asp312Asn
(rs1799793)
0.30 0.34 0.041 0.922 0.91
(0.60–1.42)
2.12
(1.12–4.01)
1.14
(0.72–1.62)
0.445
ERCC2 Lys751Gln
(rs13181)
0.31 0.37 0.163 0.673 1.45
(0.92–2.01)
1.54
(0.88–2.67)
1.43
(0.91–2.10)
0.453
MSH2 -118T.C
(rs2303425)
0.17 0.17 0.812 0.930 0.86
(0.67–1.43)
1.39
(0.57–4.05)
0.88
(0.67–1.58)
0.367
MSH2 IVS1+9G.C
(rs2303426)
0.48 0.56 0.052 0.849 1.15
(0.73–1.79)
1.83
(1.13–3.14)
1.34
(0.89–2.18)
0.492
OGG1 Ser326Cys
(rs1052133)
0.23 0.29 0.070 0.044 1.32
(0.91–1.90)
2.48
(1.13–5.42)
1.78
(1.22–2.63)
0.502
OGG1 IVS4-15C.G
(rs2072668)
0.33 0.42 0.027 0.338 1.52
(1.01–2.29)
2.01
(1.22–3.58)
1.63
(1.14–2.43)
0.531
XRCC1 Arg194Trp
(rs1799782)
0.11 0.12 0.618 0.933 0.94
(0.58–1.54)
1.68
(0.27–10.25)
0.92
(0.59–1.57)
0.390
XRCC1 Arg399Gln
(rs25487)
0.44 0.32 ,0.001 0.128 0.57
(0.37–0.87)
0.44
(0.22–0.76)
0.55
(0.35–0.86)
0.598
PTGS2 -1195G.A
(rs689466)
0.13 0.23 ,0.001 0.023 1.99
(1.17–3.40)
7.04
(2.23–22.19)
2.54
(1.55–4.16)
0.599
PTGS2 -765G.C
(rs20417)
0.08 0.18 ,0.001 0.056 1.91
(1.23–2.97)
2.74
(0.95–7.90)
1.99
(1.31–3.05)
0.612
PTGS2 Ex10+837T.C
(rs5275)
0.39 0.42 0.334 0.692 1.40
(0.91–2.16)
1.34
(0.74–2.45)
1.39
(0.92–2.09)
0.408
TLR2 –196 to
–74del
0.19 0.23 0.091 0.364 1.51
(1.02–2.24)
2.14
(0.56–8.11)
1.54
(1.05–2.26)
0.465
TLR4 Thr399Ile
(rs4986791)
0.06 0.09 0.021 0.445 1.74
(0.96–3.16)
7.57
(0.83–69.28)
1.96
(1.11–3.49)
0.504
CASP8 -652 6N ins/del
(rs3834129)
0.29 0.20 0.005 0.154 0.66
(0.44–0.98)
0.42
(0.20–0.89)
0.61
(0.42–0.88)
0.539
CASP8 IVS12-19G.A
(rs3769818)
0.14 0.16 0.375 0.803 1.33
(0.87–2.02)
0.83
(0.18–3.89)
1.30
(0.86–1.96)
0.414
CASP8 Asp302His
(rs1045485)
0.04 0.05 0.421 0.894 1.36
(0.70–2.64)
0.95
(0.06–15.5)
1.33
(0.69–2.56)
0.402
aAdjusted for age and gender in logistic regression model, Significant values are denoted as bold.
FPRP, false-positive report probability based on ORdom (assuming prior probability of 0.05 and power to detect an OR of 2.0 or 0.5).
ORhet, odds ratio of heterozygote vs. common homozygote genotypes, ORhom, odds ratio of rare homozygote vs. common homozygote genotypes, ORdom, odds ratio of
heterozygote+variant homozygote vs. common homozygote genotypes.
bProbability of association in genomic control method (Minimum=0.5).
doi:10.1371/journal.pone.0016449.t002
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of GBC (OR=0.66; OR=0.42, respectively (Table 2) with the ‘del’
allele being associated with the decreased risk of gallbladder cancer in a
dose-dependent manner (Ptrend =0.003). Furthermore, a significant
decreased risk of GBC was found with the CASP8 -652 (ins/del + del/
del genotypes) compared with the -652 6N ins/ins genotype, suggesting
a dominant protective effect of this polymorphism on GBC
(OR=0.61; 95% CI=0.42-0.88; Ptrend=0.005). No significant
association was found between IVS12-19G.Aa n dE x 1 3 +51G.C
polymorphisms and overall GBC risk.
Association of PTGS2 polymorphisms with GBC. On
comparing the genotype frequency distribution in GBC patients
with that of controls, the frequency of PTGS2 -1195 heterozygote
and variant homozygote genotypes were associated with significant
increased risk (OR=1.99; OR=7.04; respectively) for GBC
(Table 2). The trend test was also significant (Ptrend,0.001). The
risk due to variant-containing genotypes (GA+AA) was significant
(P,0.001; OR=2.54) when compared with homozygous
wild-type GG genotype. The PTGS2 -765 GC genotype was
also associated with significant increased risk (OR=1.91;
95%CI=1.23-2.97) for GBC (Table 2). The trend test was also
significant (Ptrend,0.001). However, none of the genotypes of
PTGS2 +8473T.C polymorphisms were significantly associated
with susceptibility of gallbladder cancer (Table 2).
Association between TLR polymorphisms and GBC
risk. Table 3 shows the GBC risk related to the TLR2 (D22)
and TLR4 (Ex4+936C.T) polymorphisms. In the present study,
we found that both heterozygote and variant homozygote
genotypes of both the TLR polymorphisms were associated with
increased risk of GBC (OR=1.51; OR=2.14; Ptrend=0.091;
Table 2). Furthermore, a significant increased risk of GBC was
found with the TLR2 (D22) (ins/del + del/del genotypes) as
compared with D22 ins/ins genotype, suggesting a dominant effect
model involved in the risk of this polymorphism on GBC
(OR=1.54; 95% CI=1.05-2.26; Ptrend=0.117).
The TLR4 Ex4+936C.T polymorphism was also found to be
significantly associated with the overall GBC risk under a
dominant mode of inheritance (OR=1.96; 95% CI=1.11-2.26;
Ptrend=0.021).
CART Analysis
Figure 1 depicts the tree structure generated using the CART,
which included all investigated genetic variants of the DNA repair,
apoptotic and inflammatory pathway. The final tree structure
contained six terminal nodes as defined by single-nucleotide
polymorphisms of the DNA repair, apoptotic and inflammatory
pathway genes. The OGG1 Ser326Cys genotype was singled out in
the first splitting node, separating individuals with the wild type–
containing genotypes (low risk) from subjects with the homozygous
variant genotype (high risk). Individuals with the variant genotypes
of CASP8 Asp302His, TLR4 Thr399Ile and wild type genotypes of
OGG1 Ser326Cys, PTGS2 -765G.C exhibited the lowest GBC
risk with a 10% case rate (Fig. 1). Table 3 summarizes the risk
associated with all the terminal subgroups compared with the
subgroup with the least case percentage (Node 1). Table 4 shows
the OR estimates generated for the three different risk groups
determined on the basis of the case ratio of each CART terminal
node. Compared with the low-risk group combining terminal
nodes with a case ratio less than 40%, the medium-risk (case ratio
between 40% and 70%) and high-risk groups (case ratio more than
70%) were both associated with a significantly increased GBC risk
with ORs of 3.08 (95% CI=1.98-4.77) and 10.04 (95% CI=4.76-
21.19), respectively (Ptrend,0.001).
GoM Analysis
Six groups categorized the data distinguishing high from how
intrinsic risk for GBC with respect to the examined variants (Table
S2): Groups I, II, and III were the control subjects (low-risk);
groups IV, V and VI were the GBC patients (high-risk) (Table S2).
Low-risk groups. The low intrinsic risk (without disease) was
characterized by multiple protective genotypes (i.e., groups I, II
and III) (Table S2). These low-risk sets had the most common
genotypes for the studied variables over-represented, denoting
protection. Some of the variant alleles were also over-represented
in the low-risk sets implying that many control subjects carried
some risk for GBC. Group I had the age at enrolment of 56–60
years. The group included around 89% female subjects. They
were 100% carriers of the wild allele for the PTGS2 (-1195G.A),
with a QRF of 1.54. A QRF of one is neutral. Group II were
100% carriers of the OGG1 (IVS4-15C.G) ‘C’ allele and OGG1
Ser326Cys ‘Cys’ allele with a QRF of 1.29 and 1.30, respectively.
50% of this group also carried MSH2 (IVS1+9G.C) variant ‘C’
allele. Group III were heterozygous wild for the TLR4 Thr399Ile
and TLR2 –196 to –174del variant allele with a QRF of 1.55 and
1.44 respectively. This group was also homozygous for PTGS2
-765G.C and XRCC1 Arg194Trp wild type alleles.
Table 3. Risk estimates of CART terminal nodes.
Node Genotype of Individuals in Each Node Case Control Case Rate
a (%)
Adjusted OR
b (95%
CI)
Node 1 OGG-326(W) + PTGS-765(W) + TLR-399(M) + CASP-302(M) 1 9 10.0 Reference
Node 2 OGG-326(W) + PTGS-765(W) + TLR-399(W) + CASP-302(W) 55 109 33.5 3.21 (0.37–27.41)
Node 3 OGG-326(M) + PTGS-1195(W) + PTGS-8473(W) 18 31 36.7 3.95 (0.44–35.79)
Node 4 OGG-326(M) + PTGS-1195(W) + PTGS-8473(M) + XRCC-399(M) 25 32 43.9 5.30 (0.59–47.29)
Node 5 OGG-326(W) + PTGS-765(M) 38 19 66.7 13.78 (1.54–123.46)
Node 6 OGG-326(M) + PTGS-1195(M) 43 19 69.4 13.84 (1.55–123.72)
Node 7 OGG-326(M) + PTGS-1195(W) + PTGS-8473(M) + XRCC-399(W) 27 11 71.1 18.47 (1.97–173.12)
Node 8 OGG-326(W) + PTGS-765(W) + TLR-399(M) + CASP-302(W) 18 0 100.0 -
Node 9 OGG-326(W) + PTGS-765(W) + TLR-399(W) + CASP-302(M) 5 0 100.0 -
aCase rate is the percentage of cancer patients among all individuals in each node [case/(case + control) x 100].
bAdjusted for age and gender.
doi:10.1371/journal.pone.0016449.t003
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IV: OGG1 (IVS4-15C.):CG, PTGS2 (-1195G.A):GA, MSH2
(-118T.C):CC and OGG1 Ser326Cys:GG (onset 46-60 years); V:
OGG1 (IVS4-15C.):GG, and OGG1 Ser326Cys:CG (onset 46–60
years); and VI: ERCC2 Asp312Asn:AA, ERCC2 Lys751Gln:CC
and TLR2 –196 to –174del:ID (onset 46–55 years) (Table S2).
OGG1 (IVS4-15C.G) and OGG1 Ser326Cys polymorphisms
were the influential variants in defining group IV as indicated by
elevated question relevance factor (QRF or the relevance of a
variable to a pure type, with a lower limit of zero) scores of 1.26
and 1.21, respectively. This group was also homozygous for the
MSH2 promoter polymorphism at position -118 (CC). Group V
were mostly females and had their age-of-onset as 46-60 years.
They carried 100% probability for carrying OGG1 (IVS4-15C.):
GG genotype, and were 100% heterozygous for OGG1 Ser326Cys
polymorphism. The QRFs for these genetic variants were 1.66 and
1.21 respectively which defined the group. Group VI had age of
onset at 46-55 years. There were more females (91%) in this
group. All were homozygous for ERCC2 Lys751Gln (CC) and
ERCC2 Asp312Asn (AA) with a QRF of 1.46 and 2.19, respec-
tively. This group was also almost heterozygous for TLR2 –196 to
–174del (ID) polymorphism.
To find out the risk associated with each high-intrinsic set, we
categorized the individuals on the basis of combination of
genotypes that defined the set. Logistic regression analysis found
that individuals in set I were at 3 fold increased risk of GBC
(P=0.033, 95% CI=1.09-8.61). Individuals in set II were at 1.7
fold increased risk for GBC (P=0.010, 95% CI=1.13-2.51) while
set III conferred .2 fold increased risk for GBC (P=0.013, 95%
CI=1.18-4.16) (Table 5).
Informative variables. Information content for each
variable was estimated by ‘H’ statistic (Shannon, Bell Labora-
tories). H close to 0 indicates similar outcome frequencies for each
set (Table S2). Higher values represent increasing information
content. OGG1 (IVS4-15C.G), OGG1 Ser326Cys, ERCC2
Lys751Gln and ERCC2 Asp312Asn had H .0.75. H.0.50 was
seen in MSH2 (IVS1+9G.C), MSH2 (-118T.C) and PTGS2
(-1195G.A). These are the variables strongly determining the risk
for sets I to VI (Table S2).
Membership in the risk sets. Graded membership scores
were automatically generated for each subject ranging from zero
(no resemblance) to one (exact match) according to maximum
likelihood estimation procedure. The sizes of the high intrinsic risk
groups were 78.0, 55.9 and 36.5, respectively. The sizes of the low
intrinsic risk groups were 80.5, 115.0 and 93.9, respectively (Table
S2).
Discussion
Carcinoma of the gallbladder (GBC) is a relatively rare
malignancy with poor prognosis and high fatality rate affecting
females two to three times more commonly than males.[2] Several
epidemiologic studies have indicated the role of genetic factors in
the pathogenesis of GBC by modifying the risk involved
Figure 1. CART analysis of genetic variants in DNA repair, Apoptotic and Inflammatory pathway genes in modulating GBC risk.
W=common homozygote genotypes, M=heterozygote+variant homozygote genotypes.
doi:10.1371/journal.pone.0016449.g001
Table 4. Combined analysis of the effects of genetic variants
in the DNA repair, apoptotic and inflammatory pathways on
GBC risk based on the results of the CART analysis.
Risk group
a Control/Case (N) OR (95% CI)
b P-value
Low-risk 109/74 1.0 -
Medium-risk 70/106 3.08(1.98–4.77) ,0.001
High-risk 11/50 10.04(4.76–21.19) ,0.001
Ptrend ,0.001
aLow risk: case ratio,40, medium risk: 40#case ratio,70, high risk: case
ratio$70.
bAdjusted for age and gender.
doi:10.1371/journal.pone.0016449.t004
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results and there are difficulties in validating and replicating them.
GBC being a multifactorial and multistep disease, there may be
a complex interaction between multiple risk alleles acting in a
stronger manner in a combination rather than individually. So to
achieve a more comprehensive evaluation of GBC risk considering
several genetic variants simultaneously, present analysis was
carried out in order to identify high and low intrinsic risk sets of
gene variants. Of the included 16 polymorphisms, some of them
were found to be significantly associated with GBC risk in our
previous preliminary studies while others showed little or no
influence on the risk for GBC development [4,27,28].
For the higher order gene-gene interaction analysis, we
employed 2 statistical approaches namely CART and GoM
analysis to find out the particular combinations of genetic variants
contributing to GBC risk.
In CART analysis, which is a non-parametric statistical
approach for conducting regression and classification analyses by
recursive partitioning [29], the study subjects were grouped
according to different risk levels on the basis of the different gene
polymorphisms. From this analysis, we found that development of
GBC involves complex genetic interactions among the DNA
repair, apoptotic and inflammatory pathway gene variants.
However, our results should be interpreted with caution because
of the limited number of subjects in some of the CART terminal
nodes.
In the GoM analysis, which includes all the predictors in a single
model thus avoiding very large tested groups, and multiple
comparison problems, six risk sets were identified for the present
data defining three low intrinsic risk sets (I-III) and three high
intrinsic risk sets (IV-VI), varying on the basis of age and
significant risk alleles. The present approach automatically
categorizes individuals to risk sets on the basis of graded member-
ship scores.
The high intrinsic risk (sets IV to VI) was described by the
presence of multiple risk alleles while the low intrinsic risk (sets I-
III) was characterized by multiple protective alleles. Similarity to
the high intrinsic risk sets carried ,3-fold elevated risk for GBC.
Risk factors for Group IV were OGG1 (IVS4-15C.):CG and
OGG1 Ser326Cys:GG. However, PTGS2 (-1195G.A):GA and
MSH2 (-118T.C):CC were also relevant. Risk factors for Group
V had OGG1 (IVS4-15C.):CG and OGG1 Ser326Cys:GG as the
most prevalent risk factors of GBC. That for Group VI was the
promoter polymorphism in TLR2 at –196 to –174 (ID) along with
ERCC2 Asp312Asn:AA and ERCC2 Lys751Gln:CC genotypes.
The GoM analysis revealed the importance of two OGG1
polymorphisms along with PTGS2 -1195G.A polymorphism in
susceptibility to GBC risk. This was evident from the fact that the
set IV and set V were harbouring both the OGG1 polymorphisms.
The human DNA repair enzyme, OGG1, is a DNA
glycosylase/AP lyase that efficiently repairs 8-hydroxy-29-deox-
yguanosine (8-OHdG), one of the most abundant oxidative
products in DNA. 8-OHdG is highly mutagenic in vitro and in
vivo giving rise to GC to TA transversions on DNA replication,
which is frequent in several oncogenes and tumor suppressor genes
[30,31]. We had earlier reported an association between OGG1
Ser326Cys polymorphism in a case-control study for GBC [28].
Also, significant association has been observed between OGG1
Ser326Cys polymorphism and risk of esophageal [32], lung [33],
bladder [34], breast [35] and colon [36] cancers. In addition to
OGG1 Ser326Cys, we also evaluated the influence of another
polymorphism of OGG1 gene present in Intron 4 (IVS4-15C.G).
This is an intronic polymorphism residing in Intron 4 of OGG1
gene and frequent allelic imbalance in this region has been shown
to be involved in head and neck squamous carcinogenesis [37]. It
seems that this polymorphism is involved in the splicing of OGG1
mRNA. All the three high risk sets (IV, V and VI) were 100%
carriers of the variant allele of OGG1 polymorphisms.
PTGS2 over-expression has been observed in malignancies of
various organs such as colorectum, lung, breast, prostate, bladder,
stomach, and esophagus [38]. The PTGS2 promoter region
contains binding sites for several key cis acting regulatory elements
[39]. Present study signified the role of PTGS2 -1195G.A
polymorphism in GBC pathogenesis. Studies have shown that
-1195A allele is able to bind c-MYB, one of the important
transcription-factor that activates PTGS2 expression. c-MYB is
required to keep a balance between cell division, differentiation
and survival [40]. Luciferase assays have also shown significantly
increased transcriptional activity of PTGS2 gene in the individuals
carrying -1195A allele [41,42]. The elevated levels of PTGS2 leads
to overproduction of prostaglandins (PGE2) which, being pro-
carcinogenic, can prop up tumor growth by various signaling
pathways controlling angiogenesis, cell proliferation, suppression
of immune responses, invasiveness and also by inhibiting tumor
cells apoptosis [43,44,45]. Another PTGS2 polymorphism the
-765G.C (rs20417), was also found to be modulating the risk of
GBC in our multigenic model. This polymorphism is located
within a putative Stimulatory protein 1 (SP1) binding site that leads to
a 30% reduction of the PTGS2 promoter activity in vitro [46].
Although the exact molecular mechanism by which this
polymorphism may affect the risk of GBC development is still
unclear, studies in the PTGS2 promoter revealed that PTGS2
transcription is activated by E2 promoter binding factor 1 (E2F1)
[47], which is dependent on the transactivation and DNA-binding
domains of E2F1 [48]. So the ability of this polymorphism to
create an E2F binding site, essential for the expression of several
genes [49], might help us to understand why we observed
increased risk.
The phenomenon that a combination of polymorphisms within
genes of unrelated pathways may elevate the risk for GBC could
be explained by two hypotheses. One possibility is that some
connection between these genes or proteins exists but still remains
to be discovered. Another hypothesis, more probable in our
opinion, is that the genes influencing risk for GBC may as well
Table 5. Gallbladder cancer (GBC) risk associated with risk groups based on GoM.
Set Genotype of Individuals in Each Set OR
a (95% CI) P-Value
Set 1 OGG1-326 (GG) + OGG1-IVS4-15C.G (CG) + MSH2-118T.C (CC) + PTGS2-1195G.A (GA) 3.07 (1.09–8.61) 0.033
Set 2 OGG1-326 (CG) + OGG1-IVS4-15C.G (GG) 1.69 (1.13–2.51) 0.010
Set 3 ERCC2-312 (AA) + ERCC2-751 (CC) + TLR2-D22 (ins,del) 2.22 (1.18–4.16) 0.013
aAdjusted for age and gender.
doi:10.1371/journal.pone.0016449.t005
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each other. Such an unfavourable genetic profile could finally lead
to appearance of the disease, although particular genes do not
share any common functions and separately evoke a little or
unnoticeable effect. Moreover, there may be multiple sufficient
risk sets for GBC. Looking at multiple genes together rather than
analyzing them individually may improve identification of risk
alleles. In the present study, both GoM and CART categorized the
GBC patients into high and low risk groups on the basis of
analyzed polymorphisms.
Our study has several strengths like all our control subjects were
under Hardy-Weinberg equilibrium minimizing population strat-
ification, all our cases were histopathologically confirmed
minimizing misclassification of outcome and cases and controls
were matched for age and gender. The selection and survival
biases in our study were negligible due to almost complete case
ascertainment and high response rates. Strict quality control for
genotyping was used, minimizing the potential for genotype
misclassification. To limit potential confounding false positive
associations due to moderate sample size and population
stratification, we used software as described by Wacholder et al.
[18] to filter out false-positive associations by setting very rigorous
prior probabilities.
Limitations and sources of bias should be considered. Like all
other case-control studies, inherent biases like selection bias and
recall bias in the present study may have led to some spurious
results. Although, the inclusion of SNPs in our study was based on
potential functional role in genes with higher potential of being
associated to cancer risk, a more comprehensive approach
including tagging SNPs would present more convincing support
for the associations. There is genetic variation within other genes
we did not evaluate and the selected genes we studied in the study.
However it is worth mentioning that the control cohort was
gallstone negative which could present a bias in the obtained
results as gallstone disease is an established risk factor for GBC.
Also the relatively small sample size of our study might prevent
some observed effects of genetic polymorphisms from reaching
statistical significance. A more comprehensive approach including
environmental factors would probably further improve the results.
In summary, the present study is one of the first to use a
polygenic strategy to evaluate the involvement of DNA repair,
apoptotic and inflammatory pathway gene polymorphisms in
gallbladder carcinoma. Our results indicate that CART and GoM
can play an important role as statistical tools in genetic association
studies to detect unknown interactions among the risk-associated
SNPs with marginal effects. Moreover, because the data is
analyzed simultaneously, multiple comparisons are avoided. The
advantage of using cluster analysis over CART relies on the fact
that risk sets can be identified even with small sample size. Such
studies of genetic interactions, along with their biological
validations can be used to identify diagnostic procedures and
early therapeutic interference so as to prevent or significantly delay
the clinical manifestations of GBC. However, this study included
only North Indian individuals, therefore the results may not apply
to other ethnic groups.
To conclude, we identified high and low intrinsic risk profiles for
GBC from information on multiple genetic variants modulating
DNA repair, inflammation and apoptosis.
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